View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
June 4, 2020

ASCO 2020: KEYNOTE-204 positions Keytruda to displace Adcetris as the monotherapy of choice for relapsed/refractory Hodgkin lymphoma patients

By Victoria Smith

Adcetris (brentuximab vedotin) redefined Hodgkin lymphoma treatment with its approval in 2011, becoming the backbone of Hodgkin lymphoma therapy. It is currently approved in all lines of treatment. The arrival of PD-1 inhibitors such as Keytruda (pembrolizumab) and Opdivo (nivolumab) boosted treatment options for this indication.

Up to now, PD-1 inhibitors have been viewed as options following Adcetris treatment. However, results from the Phase III KEYNOTE-204 trial comparing Keytruda versus Adcetris suggest potential for Keytruda to move up in the treatment paradigm, with the potential to replace Adcetris. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology